Hepatitis C News and Research

Latest Hepatitis C News and Research

Herpevac Trial for Women finds experimental vaccine ineffective in prevention of genital herpes disease

An experimental vaccine intended to prevent genital herpes disease in women, although generally safe and well-tolerated, proved ineffective when tested in the recently concluded clinical study known as the Herpevac Trial for Women.

1 Oct 2010

Achillion initiates ACH-1625 Phase II dosing for HCV infection

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that the Company has initiated patient dosing in a Phase II clinical trial of ACH-1625 for the treatment of hepatitis C virus (HCV) infection. ACH-1625 is a potent small molecule inhibitor of HCV protease, an enzyme necessary for viral replication. The drug candidate was discovered and is being advanced by Achillion.

1 Oct 2010

Candidates who have strong religious connection have better post-transplant survival

Italian researchers report that liver transplant candidates who have a strong religious connection have better post-transplant survival. This study also finds that religiosity—regardless of cause of death—prolongs the life span of individuals who underwent liver transplantation.

1 Oct 2010

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.

30 Sep 2010

Researchers develop genetic screening method to identify drug-resistant HCV strains

In recent human trials for a promising new class of drug designed to target the hepatitis C virus (HCV) without shutting down the immune system, some of the HCV strains being treated exhibited signs of drug resistance.

30 Sep 2010

School blood test breached guidelines: Investigation report

According to a report by an Education Department, a Tasmanian teacher who conducted blood tests on 19 high school students breached guidelines. The incident happened last month when a teacher at the Dover District High School took blood samples from the students using just two lancets for a science class experiment. These lancets were cleaned between pricks using methylated spirits. These spirits are inadequate when preventing blood borne viral disease like HIV and Hepatitis say experts.

29 Sep 2010

ZymoGenetics announces positive survival data from IL-21 Phase 2a clinical trial

ZymoGenetics, Inc. today announced positive survival data from a Phase 2a clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. Median overall survival was 12.4 months, and the percentage of patients surviving at 12 months was 53%.

29 Sep 2010

Florida likely to seek waiver on medical loss ratio; Ariz. cuts back Medicaid benefits

The Hill Healthwatch: "Florida's 14-member insurance advisory board has unanimously passed a resolution to seek a waiver from the health law's medical loss ratio. An official with the Florida Office of Insurance Regulation tells The Hill that the board's vote means it's a 'done deal' that the state will formally seek some kind of waiver but the board is gathering public input through Oct. 8.

29 Sep 2010

AASLD, TFAH report calls for action to help identify Americans living with HBV, HCV

The American Association for the Study of Liver Diseases and the Trust for America's Health issued a new report today calling for action to be taken to transform how the country deals with viral hepatitis – to help identify millions of Americans who know they are living with chronic forms of hepatitis B and C and to assure access to treatment for all who need it, to prevent even more Americans from becoming infected.

28 Sep 2010

Novel therapies for HCV treatment can precipitate several changes: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch of novel therapies for the treatment of Hepatitis C Virus (HCV), including Vertex/Johnson & Johnson/Mitsubishi Tanabe's telaprevir and Merck's boceprevir, will precipitate several changes in HCV treatment.

28 Sep 2010

HHS Secretary announces $30M to expand HIV prevention efforts under President's NHAS

U.S. Department of Health and Human Services Secretary Kathleen Sebelius today announced that CDC has allocated $30 million of the Affordable Care Act's Prevention and Public Health Fund to expand HIV prevention efforts under the President's National HIV/AIDS Strategy. This includes $21.6 million in grants to state and local health departments.

27 Sep 2010

HHS announces grants to support public health programs

Six months after the Affordable Care Act was signed into law, U.S. Department of Health and Human Services Secretary Kathleen Sebelius highlighted another important facet of the law today with the announcement of nearly $100 million in grants made possible primarily by the new law's Prevention and Public Health Fund.

27 Sep 2010

ARTES acquires ANAVAX virus-like particle technology from Select Vaccines

ARTES Biotechnology announces today the acquirement of the ANAVAX virus-like particle (VLP) technology from Select Vaccines Ltd. ANAVAX is a patent-protected VLP technology that can be applied to the prevention of several infectious diseases.

27 Sep 2010

Comic books to educate young men about testicular cancer

Comic books may help to educate young men and their partners about testicular cancer and its early symptoms and encourage them to do more self-screening, according to Ryerson University School of Fashion professor and comic book artist David Brame.

24 Sep 2010

AJMS journal provides research update on new infectious pathogens

Newly recognized disease-causing viruses, bacteria, and other infections are continually emerging around the world, posing difficult challenges for patient diagnosis and treatment and for public health responses. A special symposium section of the September issue of The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation, provides a research update on important new infectious pathogens.

24 Sep 2010

Merck expands patient assistance programs to provide medicines to needy people

Today, Merck announced that it has significantly expanded the number of Merck medicines available through its Merck Helps patient assistance programs, which include the Merck Patient Assistance Program, the Merck Vaccine Patient Assistance Program, the ACT Program for Oncology and Hepatitis C medicines, and the SUPPORT Program for HIV/AIDS medicines.

23 Sep 2010

FDA approves Roche's COBAS AmpliPrep / COBAS TaqMan HBV Test v2.0

Roche Molecular Diagnostics announced today that the U.S. Food & Drug Administration (FDA) has approved the COBAS® AmpliPrep / COBAS® TaqMan® HBV Test v2.0 for use in the United States. The new Roche test provides a fully automated solution for the quantitative detection of hepatitis B virus (HBV) DNA in human plasma or serum for patients on HBV antiviral therapy.

23 Sep 2010

Scientists create human liver cells using stem cells

Emerging Healthcare Solutions President and CEO Cindy Morrissey said Tuesday that a recent study at the University of Cambridge seems to indicate that realistic stem cell therapies to replace diseased or damaged tissues may be closer than ever.

23 Sep 2010

NanoViricides enters agreement with Seaside to purchase Series B Convertible Preferred Stock

NanoViricides, Inc., announced today that it had reached an agreement with Seaside 88, LP a Florida limited partnership, for the exercise of Seaside's option to purchase an additional $2.5M of the Company's Series B Convertible Preferred Stock.

23 Sep 2010

Weight-based taribavirin reduces anemia, increases sustained virologic response

Researchers at Cedars-Sinai Medical Center and 50 other centers found that weight-based dosing of taribavirin reduces rates of anemia while increasing sustained virologic response (SVR) in patients with chronic hepatitis C (HCV). Full details of this study are available in the October issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

23 Sep 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

Herpevac Trial for Women finds experimental vaccine ineffective in prevention of genital herpes disease

Achillion initiates ACH-1625 Phase II dosing for HCV infection

Candidates who have strong religious connection have better post-transplant survival

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Researchers develop genetic screening method to identify drug-resistant HCV strains

School blood test breached guidelines: Investigation report

ZymoGenetics announces positive survival data from IL-21 Phase 2a clinical trial

Florida likely to seek waiver on medical loss ratio; Ariz. cuts back Medicaid benefits

AASLD, TFAH report calls for action to help identify Americans living with HBV, HCV

Novel therapies for HCV treatment can precipitate several changes: Report

HHS Secretary announces $30M to expand HIV prevention efforts under President's NHAS

HHS announces grants to support public health programs

ARTES acquires ANAVAX virus-like particle technology from Select Vaccines

Comic books to educate young men about testicular cancer

AJMS journal provides research update on new infectious pathogens

Merck expands patient assistance programs to provide medicines to needy people

FDA approves Roche's COBAS AmpliPrep / COBAS TaqMan HBV Test v2.0

Scientists create human liver cells using stem cells

NanoViricides enters agreement with Seaside to purchase Series B Convertible Preferred Stock

Weight-based taribavirin reduces anemia, increases sustained virologic response

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis C News and Research

Latest Hepatitis C News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in